Neurocrine's Depression Drug Fails Phase 2 Goal But Shows Encouraging Safety Profile

On Monday, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) said its Phase 2 study of NBI-1070770 in adults with major depressive disorder did not meet the primary endpoint compared to placebo, though it was generally well tolerated.Neurocrine Biosciences acquired the rights to develop and commercialize NBI-1070770 from Takeda Pharmaceutical Company, Ltd. (NYSE:TAK)The Phase 2 study was designed to evaluate the efficacy, safety, and tolerability of three dosage strengths of adjunctive NBI-1070770 compared to plac ...